Lung Cancer Clinical Trial

CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC

Summary

The objective of this study is to assess safety and efficacy of CAB-AXL-ADC in NSCLC

View Full Description

Full Description

This is a multi-center, open-label, Phase 2 study designed to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of BA3011, a conditionally active biologic (CAB) AXL-targeted antibody drug conjugate (CAB-AXL-ADC), alone and in combination with PD-1 inhibitor in patients with metastatic non-small cell lung cancer (NSCLC).

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patients must have measurable disease.
Age ≥ 18 years
Adequate renal function
Adequate liver function
Adequate hematological function
Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Life expectancy of at least three months.

Exclusion Criteria:

Patients must not have clinically significant cardiac disease.
Patients must not have known non-controlled CNS metastasis.
Patients must not have had prior therapy with a conjugated or unconjugated auristatin derivative/vinca-binding site targeting payload.
Patients must not have a history of ≥ Grade 3 allergic reactions to mAb therapy as well as known or suspected allergy or intolerance to any agent given during this study.
Patients must not have had major surgery within 4 weeks before first BA3011
Patients must not have known human immunodeficiency virus (HIV) infection, active hepatitis B and/or hepatitis C.
Patients must not be women who are pregnant or breast feeding.

Study is for people with:

Lung Cancer

Phase:

Phase 2

Estimated Enrollment:

240

Study ID:

NCT04681131

Recruitment Status:

Recruiting

Sponsor:

BioAtla, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 28 Locations for this study

See Locations Near You

City of Hope - Duarte
Duarte California, 91010, United States More Info
Abrar Khan
Contact
[email protected]
Pathak Ranjan, MD
Principal Investigator
California Research Institute
Los Angeles California, 90027, United States More Info
Clare Gregorio
Contact
[email protected]
Ghassan Al-Jazayrly, MD
Principal Investigator
USC Norris
Los Angeles California, 90033, United States More Info
Kristina Massopust
Contact
[email protected]
Jorge Nieva, MD
Principal Investigator
Cedars-Sinai
Los Angeles California, 90048, United States More Info
Cynthia Martin
Contact
[email protected]
Sukhmani Padda, MD
Principal Investigator
American Institute of Research
Whittier California, 90603, United States More Info
Kirsten Bettino
Contact
[email protected]
Richy Agajanian, MD
Principal Investigator
University of Colorado Anschutz Medical Campus
Aurora Colorado, 80045, United States More Info
Nathan Plattner
Contact
720-848-0696
[email protected]
David Camidge
Principal Investigator
Florida Cancer Specialists & Research Institute
Fleming Island Florida, 32003, United States More Info
Sheila Gagne
Contact
904-269-6526
[email protected]
Augusto Villegas
Principal Investigator
Florida Cancer Specialists & Research Institute
Fort Myers Florida, 33916, United States More Info
Contact
239-274-9930
Ivor Percent
Principal Investigator
Florida Cancer Specialist
Saint Petersburg Florida, 33705, United States More Info
Lukas Escobar
Contact
727-216-1143
[email protected]
Vipul Patel
Principal Investigator
Florida Cancer Specialists
West Palm Beach Florida, 33401, United States More Info
De'Dra Kelly
Contact
561-366-4100
[email protected]
Eric Harris
Principal Investigator
Baptist Health Systems
Lexington Kentucky, 40503, United States More Info
Jennifer Buntain
Contact
[email protected]
Firas Badin, MD
Principal Investigator
University of Kentucky
Lexington Kentucky, 40536, United States More Info
Sarah Howard
Contact
[email protected]
Susanne Arnold, MD
Principal Investigator
Norton Cancer Institute, Brownsboro Hospital Campus
Louisville Kentucky, 40241, United States More Info
Rebecca Gash
Contact
[email protected]
Adam Lye, MD
Principal Investigator
Hematology/Oncology Clinic
Baton Rouge Louisiana, 70809, United States More Info
Aimee Alumbaugh
Contact
225-761-3951
[email protected]
Michael Castine
Principal Investigator
Dana-Farber Cancer Institute
Boston Massachusetts, 02215, United States More Info
Stefania Molinaro
Contact
[email protected]
Julia Rotow, MD
Principal Investigator
University of Michigan Comprehensive Cancer Center
Detroit Michigan, 48202, United States More Info
Nausheen Virk
Contact
[email protected]
Shirish Gadgeel, MD
Principal Investigator
Comprehensive Cancer Centers of Nevada
Henderson Nevada, 89014, United States More Info
Karishma Gupta
Contact
702-862-1114
[email protected]
Ramalingam Ratnasabapathy
Principal Investigator
OptumCare Cancer Care
Las Vegas Nevada, 89169, United States More Info
Valerie Littlefield
Contact
702-384-0013
[email protected]
John Ellerton
Principal Investigator
Roswell Park
Buffalo New York, 14263, United States More Info
Julianne Hergenroder
Contact
800-767-9355
[email protected]
Grace Dy, MD
Principal Investigator
NYU Langone Health
New York New York, 10016, United States More Info
Zaykov Viktor
Contact
[email protected]
Elaine Shum, MD
Principal Investigator
FirstHealth Outpatient Cancer Center
Pinehurst North Carolina, 28374, United States More Info
Julie Williams
Contact
910-715-1922
[email protected]
Charles Kuzma
Principal Investigator
Gabrail Cancer Research Center
Canton Ohio, 44718, United States More Info
Deshpal Bali
Contact
330-492-3345
[email protected]
Nashat Gabrail
Principal Investigator
The Lindner Research Center at the Christ Hospital
Cincinnati Ohio, 45219, United States More Info
Abby Reed
Contact
[email protected]
Alexander Starodub, MD
Principal Investigator
UPMC Cancer Center
Pittsburgh Pennsylvania, 15232, United States More Info
Liza Villaruz
Principal Investigator
Medical University of South Carolina- Hollings Cancer Center
Charleston South Carolina, 29407, United States More Info
Alexandra Leitner
Contact
[email protected]
Mariam Alexander, MD
Principal Investigator
Sarah Cannon Research Institute
Nashville Tennessee, 37203, United States More Info
Ashley Scott Maheu
Contact
615-341-7875
[email protected]
Melissa Johnson
Principal Investigator
Mary Crowley Cancer Research
Dallas Texas, 75230, United States More Info
Terrell Martinez
Contact
214-658-1946
[email protected]
James Strauss
Principal Investigator
MD Anderson
Houston Texas, 77030, United States More Info
Angela McGaskey
Contact
[email protected]
Carl Gay, MD
Principal Investigator
ICON Cancer Centre
Hong Kong , , Hong Kong More Info
Alice Ng, MD
Principal Investigator
Queen Mary Hospital
Hong Kong , , Hong Kong More Info
Winnie Chan
Contact
[email protected]
Thomas Yau, MD
Principal Investigator
Hong Kong United Oncology Centre
Kowloon , , Hong Kong More Info
Katherine Chau
Contact
[email protected]
Li Yu Chung, MD
Principal Investigator
Kaoshiung Chang Gung Memorial Hospital
Kaohsiung , , Taiwan More Info
Chin-Chou Wang, MD
Principal Investigator
Taichung Veterans General Hospital
Taichung , , Taiwan More Info
Wen-Ling Chen
Contact
[email protected]
Tsung-Ying Yang, MD
Principal Investigator
National Taiwan University Hospital
Taipei , , Taiwan More Info
Fang-Syuan Lin
Contact
[email protected]
Chih-Hsin Yang, MD
Principal Investigator
Taipei Veterans General Hospital
Taipei , , Taiwan More Info
Chi-Lun Chang
Contact
[email protected]
Yuh-Min Chen, MD
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 2

Estimated Enrollment:

240

Study ID:

NCT04681131

Recruitment Status:

Recruiting

Sponsor:


BioAtla, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.